Oncology Central

Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations


Everolimus – an inhibitor of the mTOR pathway – has an established role in the treatment of advanced renal cell cancer (RCC), neuroendocrine tumors of pancreatic origin (pNET) and renal angiomyolipoma and tuberous sclerosis complex (TSC) [1]. Moreover, everolimus, combined with the aromatase inhibitor exemestane, has been approved for the treatment of postmenopausal patients with advanced breast cancer positive for the hormone receptors (HR+) and negative for the HER2 recurring or progressing after treatment with nonsteroidal aromatase inhibitors [2]. Everolimus is administered orally, at a dose of 10 mg/day continuously. At this dosage, no evidence of cumulative toxicity has been reported in clinical trials over a period of 20–52 weeks [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.